1.	PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Phase: Phase IV Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: 20050100, NCT00352703
2.	Oral Zinc Therapy for the Prevention of Mucositis Phase: Phase IV Type: Supportive care, Treatment Status: Completed Age: 18 to 70 Sponsor: Other Protocol IDs: SHEBA-06-4196-MKM-CTIL, NCT00449592
3.	Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: TaCyDexVMP7, NCT00652041
4.	AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors Phase: Phase IV Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: 2006-00055-18, NCT00415103
5.	Phase II-III Chemotherapy with Peptichemio vs Melphalan in Refractory Metastatic Breast Cancer Phase: Phase III, Phase II Type: Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: MDA-MBDT-7814
6.	Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 4 to 70 Sponsor: Other Protocol IDs: CDR0000066968, RP 98-15, RPCI-RP-9815, NCI-V99-1527, NCT00003816
7.	Phase II-III Chemotherapy with Hexamethylmelamine and L-Phenylalanine Mustard for Stage III and IV Ovarian Carcinoma Phase: Phase III, Phase II Type: Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: DFCI-75118
8.	Phase II/III Multimodality Therapy with Surgery, CTX/ADR/5-FU/TMX/FLU, plus Radiotherapy for Stage III Breast Carcinoma Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 to 69 Sponsor: Protocol IDs: WCCC-CO-8111, NCI-D81-048-515
9.	Phase II/III L-PAM/PRED/VCR vs VP-16/PRED/ADR for Stage II/III Myeloma (Summary Last Modified 12/89) Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 20 and over Sponsor: Protocol IDs: SAFR-CT-MM-2
10.	Chemotherapy with 5-FU, Streptozotocin, Spironolactone and L-PAM for Advanced Nonmeasurable Pancreatic Carcinoma (Summary last modified 06/97 ko) Phase: Phase III, Phase II Type: Treatment Status: Completed Age: no age specified Sponsor: NCI Protocol IDs: EST-5274, MAYO-706031
11.	Phase II/III Randomized Comparison of Consolidation with Intensive Chemotherapy Using CDDP/VP-16/DOX/IFF vs Myeloablative Chemoradiotherapy and Autologous Marrow Rescue and of Continuation Therapy with Isotretinoin vs No Further Therapy in High-Risk Neuroblastoma Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 0 to 18 Sponsor: NCI Protocol IDs: CCG-3891
12.	Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: Under 30 Sponsor: NCI, Other Protocol IDs: AHOD0121, CDR0000330135, COG-AHOD0121, NCT00070187
13.	Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 19 and over Sponsor: Other Protocol IDs: 01-002-0601, NCT00205751
14.	Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT Phase: Phase III, Phase II Type: Diagnostic, Treatment Status: Closed Age: 18 to 65 Sponsor: Other Protocol IDs: R08096M, 2008-003936-38, 26866138MMY2063, NCT00861250
15.	Phase III Randomized Study of Adjuvant Hyperthermic Limb Perfusion with L-PAM for Clinical Stage I Melanoma (Summary Last Modified 07/95) Phase: Phase III Type: Treatment Status: Closed Age: under 70 Sponsor: Protocol IDs: MRC-ME01, EU-94025
16.	Phase III Randomized Study of Standard Therapy with ABCM (DOX/BCNU/CTX/L-PAM) vs Intensive Therapy with C-VAMP (CTX/VCR/DOX/MePRDL) Followed by High-Dose L-PAM (with or without TBI) with Hematopoietic Rescue, Both with IFN-A Maintenance, for Previously Untreated Myeloma (Summary Last Modified 03/2001). Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Closed Age: under 65 Sponsor: Protocol IDs: MRC-LEUK-MYEL-VII, EU-94030, NCT00002599
17.	Phase III Randomized Study of Doxorubicin, Carmustine, Cyclophosphamide, and Melphalan (ABCM) With or Without Oral Cyclophosphamide and Prednisone as Induction for the First Plateau Phase in Elderly Patients With Previously Untreated Multiple Myeloma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Closed Age: 65 to 74 Sponsor: Other Protocol IDs: MRC-LEUK-MYEL-VIII, EU-94031, NCT00002653
18.	Phase III Nonrandomized Study of Therapy Based on Risk Group for Children and Adolescents with Neuroblastoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Closed Age: under 21 Sponsor: Protocol IDs: GER-NB90, EU-96004, NCT00002802
19.	Phase III Randomized Study of High-Dose Sequential Chemotherapy Followed by Peripheral Blood Stem Cell Transplantation vs Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP) for Poor-Risk, Intermediate- and High-Grade Non-Hodgkin's Lymphoma (Summary Last Modified 02/1999) Phase: Phase III Type: Treatment Status: Completed Age: 18 to 65 Sponsor: NCI Protocol IDs: E-2493, E2493
20.	Combination Chemotherapy in Treating Patients With Lymphoma Phase: Phase III Type: Treatment Status: Completed Age: 15 to 59 Sponsor: NCI, Other Protocol IDs: MDA DM95-121, P30CA016672, NCI-V96-1010, CDR0000065044, NCT00002835
21.	Phase III Randomized Study of Consolidation with Cyclophosphamide/Mitoxantrone/Melphalan Followed by Autologous Stem Cell Rescue vs Conventional Chemotherapy for Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: under 60 Sponsor: Protocol IDs: FRE-FNCLCC-PEGASE04, EU-96033
22.	High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Phase: Phase III Type: Treatment Status: Completed Age: Over 25 Sponsor: Other Protocol IDs: CDR0000065406, RPCI-DS-96-48, NCI-G97-1152, NCT00002945
23.	Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Phase: Phase III Type: Treatment Status: Closed Age: 16 to 60 Sponsor: Other Protocol IDs: CDR0000065526, EORTC-06962, NCT00002989
24.	Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma Phase: Phase III Type: Treatment Status: Completed Age: 18 to 60 Sponsor: Other Protocol IDs: SAKK 38/97, SWS-SAKK-38/97, EU-97037, NCT00003215
25.	Phase III Randomized Study of Adjuvant Therapy with or without Intensification Therapy with Autologous Peripheral Blood Stem Cell Transplantation for Women with Poor Prognosis Nonmetastatic Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: Under 60 Sponsor: Protocol IDs: FRE-FNCLCC-PEGASE01, EU-96030